T. Reungwetwattana

发表

Osimertinib in Untreated EGFR‐Mutated Advanced Non–Small‐Cell Lung Cancer

Ying Cheng, Y. Ohe, B. Chewaskulyong, 2018, The New England journal of medicine.

Progress in the Management of Malignant Pleural Mesothelioma in 2017

W. Mao, A. Mansfield, H. Pass, 2018, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

The race to target MET exon 14 skipping alterations in non-small cell lung cancer: The Why, the How, the Who, the Unknown, and the Inevitable.

S. Ou, T. Reungwetwattana, Ying-ying Liang, 2017, Lung cancer.

Determination of irinotecan, SN‐38 and SN‐38 glucuronide using HPLC/MS/MS: Application in a clinical pharmacokinetic and personalized medicine in colorectal cancer patients

C. Sukasem, T. Reungwetwattana, A. Puangpetch, 2018, Journal of clinical laboratory analysis.

Efficacy of Combination Docetaxel and Nintedanib in Advanced Non-Small Cell Lung Cancer in Thailand: A Multicenter Study

J. Chindaprasirt, T. Reungwetwattana, P. Danchaivijitr, 2021, Frontiers in Oncology.

Molecular alterations and clinical prognostic factors for cholangiocarcinoma in Thai population

C. Sukasem, T. Reungwetwattana, D. Muntham, 2017, OncoTargets and therapy.

Cost-utility analysis of adjuvant trastuzumab therapy for HER2-positive early-stage breast cancer in the Philippines

T. Reungwetwattana, A. Thakkinstian, U. Chaikledkaew, 2019, BMC Health Services Research.

Targeted therapies in development for non-small cell lung cancer

G. Dy, T. Reungwetwattana, 2013, Journal of carcinogenesis.

Scientific Advances in Lung Cancer 2015

Kenneth E. Rosenzweig, Hisao Asamura, Annette McWilliams, 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Laying the Groundwork to Confront the Final Frontier of CNS Metastasis in NSCLC with Targetable Driver Mutations.

S. Ou, T. Reungwetwattana, 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

CNS response to osimertinib vs standard of care (SoC) EGFR-TKI as first-line therapy in patients (pts) with EGFR-TKI sensitising mutation (EGFRm)-positive advanced non-small cell lung cancer (NSCLC): Data from the FLAURA study.

E. Cho, S. Ramalingam, J. Vansteenkiste, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

CNS Response to Osimertinib Versus Standard Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients With Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer.

E. Cho, S. Ramalingam, J. Vansteenkiste, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Effect of drug metabolizing enzymes and transporters in Thai colorectal cancer patients treated with irinotecan-based chemotherapy

C. Sukasem, T. Reungwetwattana, A. Puangpetch, 2020, Scientific Reports.

Correlation of UGT1A1(*)28 and (*)6 polymorphisms with irinotecan-induced neutropenia in Thai colorectal cancer patients.

C. Sukasem, T. Reungwetwattana, A. Puangpetch, 2016, Drug metabolism and pharmacokinetics.

Anti-PD-1 Antibody Treatment and the Development of Acute Pulmonary Tuberculosis.

A. Adjei, T. Reungwetwattana, 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Gastrointestinal microbiota profile and clinical correlations in advanced EGFR-WT and EGFR-mutant non-small cell lung cancer

W. Chantratita, T. Reungwetwattana, T. Suwatanapongched, 2022, BMC cancer.

Asian Thoracic Oncology Research Group (ATORG) Expert Consensus Statement on MET Alterations in NSCLC: Diagnostic and Therapeutic Considerations.

Jie Yang, N. Pavlakis, Y. Yatabe, 2022, Clinical lung cancer.

Effects of polymorphisms in the MTHFR gene on 5-FU hematological toxicity and efficacy in Thai colorectal cancer patients

C. Sukasem, T. Reungwetwattana, A. Puangpetch, 2022, Frontiers in oncology.

An international real-world analysis of efficacy and safety of lorlatinib via early or expanded access programs in patients with TKI-refractory ALK+ or ROS1+ NSCLC.

N. Syn, Dong-Wan Kim, Chia‐Chi Lin, 2020, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Pharmacogenetic Study of 5-Fluorouracil-Related Severe Toxicity in Thai Cancer Patients: A Novel SNP Detection

C. Sukasem, T. Reungwetwattana, T. Ativitavas, 2012 .

Asian Thoracic Oncology Research Group Expert Consensus Statement on Optimal Management of Stage III NSCLC

Jie Yang, M. Ahn, T. Mok, 2020 .

Lung Cancer in Thailand.

T. Reungwetwattana, Putipun Puataweepong, S. Oranratnachai, 2020, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Extracellular Vesicles from EGFR T790M/L858R-mutant Non-small Cell Lung Cancer Promote Cancer Progression

T. Reungwetwattana, A. Chairoungdua, W. Panvongsa, 2022, AntiCancer Research.

Adjuvant trastuzumab regimen for HER2-positive early-stage breast cancer: a systematic review and meta-analysis

T. Reungwetwattana, A. Thakkinstian, U. Chaikledkaew, 2019, Expert review of clinical pharmacology.

Current and Emerging Therapies in Peripheral T-cell Lymphoma: Focus on Pralatrexate

J. Molina, T. Reungwetwattana, S. Jaramillo, 2011 .

Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC.

Ying Cheng, Y. Ohe, B. Chewaskulyong, 2019, The New England journal of medicine.

MET exon 14 deletion (METex14): finally, a frequent-enough actionable oncogenic driver mutation in non-small cell lung cancer to lead MET inhibitors out of "40 years of wilderness" and into a clear path of regulatory approval.

S. Ou, T. Reungwetwattana, 2015, Translational lung cancer research.

Oncogenic pathways, molecularly targeted therapies, and highlighted clinical trials in non-small-cell lung cancer (NSCLC).

S. Weroha, J. Molina, T. Reungwetwattana, 2012, Clinical lung cancer.

Exosomal microRNAs as potential biomarkers for osimertinib resistance of non-small cell lung cancer patients.

T. Reungwetwattana, A. Chairoungdua, N. Trachu, 2021, Cancer biomarkers : section A of Disease markers.

Phase II Study of BGJ398 in Patients With FGFR-Altered Advanced Cholangiocarcinoma.

P. Philip, D. Porter, E. Van Cutsem, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Dacomitinib as first-line treatment for EGFR mutation-positive non-small cell lung cancer

T. Mok, K. Prabhash, T. Reungwetwattana, 2021 .

Efficacy of First Line Systemic Chemotherapy and Multikinase Inhibitors in Advanced Hepatocellular Carcinoma: A Systematic Review and Network Meta-Analysis

J. Attia, S. Rattanasiri, T. Reungwetwattana, 2021, Frontiers in Oncology.

Asian Thoracic Oncology Research Group expert consensus statement on optimal management of stage III non-small cell lung cancer.

M. Ahn, T. Mok, H. Onishi, 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Clinical correlations with EGFR circulating tumor DNA testing in all-stage lung adenocarcinoma.

T. Reungwetwattana, A. Jinawath, D. Muntham, 2022, Cancer biomarkers : section A of Disease markers.

A phase II trial of the Src-kinase inhibitor saracatinib after four cycles of chemotherapy for patients with extensive stage small cell lung cancer: NCCTG trial N-0621.

R. Marks, N. Foster, A. Adjei, 2014, Lung cancer.

A phase I study of the histone deacetylase (HDAC) inhibitor entinostat, in combination with sorafenib in patients with advanced solid tumors

W. Ma, A. Adjei, G. Dy, 2014, Investigational New Drugs.

Osimertinib for EGFR-Mutant Non-Small-Cell Lung Cancer Central Nervous System Metastases: Current Evidence and Future Perspectives on Therapeutic Strategies

Jie Yang, M. Tsuboi, M. Ahn, 2023, Targeted Oncology.

Primary results of ALESIA: A randomised, phase III, open-label study of alectinib vs crizotinib in Asian patients with treatment-naïve ALK+ advanced NSCLC.

L. Zhang, Se-Hoon Lee, C. Zhou, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Alectinib versus crizotinib in untreated Asian patients with anaplastic lymphoma kinase-positive non-small-cell lung cancer (ALESIA): a randomised phase 3 study.

Ying Cheng, Jin-Ji Yang, Jianxing He, 2019, The Lancet. Respiratory medicine.

Osimertinib in Untreated EGFR‐Mutated Advanced Non–Small‐Cell Lung Cancer

Ying Cheng, Y. Ohe, B. Chewaskulyong, 2018, The New England journal of medicine.

Healthcare coverage affects survival of EGFR-mutant Thai lung cancer patients

T. Reungwetwattana, P. Sanvarinda, E. Sirachainan, 2023, Frontiers in Oncology.

P3.09-08 Tumor Heterogeneity and Molecular Profile of NSCLC in Thai Population

W. Chantratita, T. Reungwetwattana, N. Trachu, 2018, Journal of Thoracic Oncology.

Economic evaluation of adjuvant trastuzumab therapy for HER2-positive early-stage breast cancer: systematic review and quality assessment

T. Reungwetwattana, A. Thakkinstian, U. Chaikledkaew, 2020, Expert review of pharmacoeconomics & outcomes research.

Expert consensus recommendations on biomarker testing in metastatic and non-metastatic non-small cell lung cancer in Asia.

Jie Yang, S. Toyooka, Y. Yatabe, 2022, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Expert Consensus Recommendations on Biomarker Testing in Metastatic and Nonmetastatic NSCLC in Asia

Jie Yang, S. Toyooka, Y. Yatabe, 2022 .

Primary results of ALESIA: Phase III, randomised open-label study of alectinib (ALC) vs crizotinib (CRZ) in Asian patients (pts) with treatment-naïve ALK+ advanced non-small-cell lung cancer (NSCLC).

Se-Hoon Lee, C. Zhou, Y. Cheng, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

LBA2_PROsimertinib vs standard of care (SoC) EGFR-TKI as first-line therapy in patients (pts) with EGFRm advanced NSCLC: FLAURA

Y. Ohe, B. Chewaskulyong, E. Cho, 2017 .

Management of acquired resistance to ALK inhibitors: repeat biopsy to characterize mechanisms of resistance does not significantly impact clinical outcomes

T. Reungwetwattana, N. Prasongsook, 2021 .

Osimertinib vs comparator EGFR-TKI as first-line treatment for EGFRm advanced NSCLC (FLAURA): Final overall survival analysis

Ying Cheng, Y. Ohe, B. Chewaskulyong, 2019, Annals of Oncology.

Osimertinib versus Standard of Care EGFR TKI as First‐Line Treatment in Patients with EGFRm Advanced NSCLC: FLAURA Asian Subset

Ying Cheng, Y. Ohe, E. Cho, 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Rapid Flare of Brain Metastases in ALK-Positive Non-Small Cell Lung Cancer after Stopping Crizotinib

T. Reungwetwattana, E. Sirachainan, J. Juengsamarn, 2017 .

Association of histologic subtypes with genetic alteration and PD-L1 expression in pulmonary adenocarcinoma

T. Reungwetwattana, P. Incharoen, Bantita Phruttinarakorn, 2020, Molecular and clinical oncology.

ALK-rearranged pulmonary adenocarcinoma in Thai Patients: From diagnosis to treatment efficacy

T. Reungwetwattana, A. Jinawath, K. Kamprerasart, 2016, World Journal of Surgical Oncology.

Longitudinal circulating tumour DNA (ctDNA) monitoring for early detection of disease progression and resistance in advanced NSCLC in FLAURA

B. Chewaskulyong, S. Ramalingam, B. Cho, 2019, Annals of Oncology.

Recommendations for the use of next-generation sequencing in patients with metastatic cancer in the Asia-Pacific region: a report from the APODDC working group

J. Chiu, I. Tan, B. Tran, 2023, ESMO open.

LBA6_PROsimertinib vs standard of care (SoC) EGFR-TKI as first-line treatment in patients with EGFR-TKI sensitising mutation (EGFRm) positive advanced non-small cell lung cancer (NSCLC): FLAURA Asian subset

Ying Cheng, Y. Ohe, B. Chewaskulyong, 2017 .

Preloading magnesium attenuates cisplatin-associated nephrotoxicity: pilot randomized controlled trial (PRAGMATIC study)

T. Reungwetwattana, A. Nongnuch, C. Kitiyakara, 2021, ESMO open.

Osimertinib in Untreated EGFR-Mutated Advanced Non–Small-Cell Lung Cancer

Ying Cheng, Y. Ohe, B. Chewaskulyong, 2018 .

Lazertinib Versus Gefitinib Tyrosine Kinase Inhibitors in Treatment-Naíve Patients With EGFR-Mutated Advanced NSCLC: Analysis of the Asian Subpopulation in LASER301.

M. Ahn, B. Cho, S. How, 2023, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Lazertinib Versus Gefitinib as First-Line Treatment in Patients With EGFR-Mutated Advanced Non–Small-Cell Lung Cancer: Results From LASER301

Jie Yang, M. Ahn, Dong-Wan Kim, 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Brief Report: A Phase II “Window-of-Opportunity” Frontline Study of the mTOR Inhibitor, Temsirolimus Given as a Single Agent in Patients with Advanced NSCLC, an NCCTG Study

J. Jett, S. Mandrekar, R. Marks, 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

P3.02b-017 Sequence of EGFR-TKI Therapy and BIM Deletion Polymorphism Affect the Outcome of Treatment in EGFR Positive NSCLC

T. Reungwetwattana, D. Muntham, N. Trachu, 2017 .

A Phase II Study of Osimertinib in Patients with Advanced-Stage Non-Small Cell Lung Cancer following Prior Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR TKI) Therapy with EGFR and T790M Mutations Detected in Plasma Circulating Tumour DNA (PLASMA Study)

S. Lim, Q. Ou, T. Reungwetwattana, 2023, Cancers.

Top 20 EGFR+ NSCLC Clinical and Translational Science Papers That Shaped the 20 Years Since the Discovery of Activating EGFR Mutations in NSCLC. An Editor-in-Chief Expert Panel Consensus Survey.

M. Garassino, V. Sriuranpong, J. Tanizaki, 2024, Lung Cancer.

Molecular alterations and clinical prognostic factors in resectable non-small cell lung cancer

T. Reungwetwattana, T. Ativitavas, D. Muntham, 2024, BMC cancer.